Frontier IP Matthew White joining the Group as Director of Commercialisation

Neil Crabb, Chief Executive of Frontier IP, said: “It is a real pleasure to welcome Matthew to the Frontier IP team. His superb range of skills and experience provide an excellent match for the work many of our portfolio companies are undertaking.”

Frontier IP (LON:FIPP), which specialises in commercialising university intellectual property, today announced that Matthew White, the Head of Innovation at AB Sugar, one of the world’s largest sugar producers and a wholly-owned subsidiary of AB Foods, is joining the Group as Director of Commercialisation, in a non-board role.

Matthew has 23 years’ experience in technology, product and service innovation, business development and marketing. As AB Sugar’s Head of Innovation, he was responsible for defining strategy and managing a global innovation portfolio. The role involved working extensively with university partners on collaborative research programmes totalling over £20million.

Before joining AB Sugar, Matthew was Director of Consumer Products for international technology consulting and product development business Sagentia Limited, working across a wide range of sectors.

He started his career at Neotronics Scientific, one of the first companies to commercialise electronic odour sensing. He has a Natural Sciences degree majoring in Chemistry from the University of Cambridge.

Matthew White, said: “It is fantastic to be joining everyone at Frontier IP. I am looking forward to using my network and experience to accelerate the commercialisation activities of our exciting portfolio.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Frontier IP Group Plc

    More articles like this

    Frontier IP Group Plc

    Frontier IP Group Plc Bosch UK to work with Pulsiv Solar

    Frontier IP Group Plc (LON:FIPP), a specialist in commercialising university intellectual property, today announces that Robert Bosch Limited has entered into an agreement to work with portfolio company Pulsiv Solar to optimise the design of the

    Frontier IP Group Plc

    Frontier IP – Exscientia reaches first major milestone with GSK

    Frontier IP (LON:FIPP), a specialist in commercialising university intellectual property, today noted yesterday’s announcement from portfolio company Exscientia , a world leader in artificial intelligence (“AI”) drug discovery, that it has achieved its first major milestone

    Frontier IP Group Plc

    Frontier IP Group Fieldwork Robotics wins Innovate UK ISCF grant

    Frontier IP Group (LON:FIPP), a specialist in commercialising university intellectual property, today announced portfolio company Fieldwork Robotics (the “Company” or “Fieldwork”) has won a UK government Innovate UK Industrial Strategy Challenge Fund grant to accelerate development

    Frontier IP Group Plc

    Frontier IP Matthew White has joined the Board

    Frontier IP (LON:FIPP), a specialist in commercialising university intellectual property, today announced that Matthew White has joined the Board of Frontier IP with immediate effect. Matthew was appointed to the senior management team of Frontier IP

    Frontier IP Group Plc

    Major deal for AI drug discovery firm Exscientia

    A Dundee University spin-out firm which uses artificial intelligence (AI) to speed up drug discovery has entered a multi-million pound partnership with a US biopharma company. Under the deal, Exscientia will work on three therapeutic programmes

    Frontier IP Group Plc

    10 ways the University of Plymouth changed the world

    The University of Plymouth is helping up to 4,000 businesses a year to develop new products and help the environment – and some of those companies are changing the world right now. Developing a vaccine for

    Frontier IP Group Plc

    Frontier IP Amprologix wins DHSC backing for new antibiotic

    Neil Crabb, chief executive officer of Frontier IP, said: “We are delighted the SBRI is backing this programme, which validates our approach to IP commercialisation. Through Amprologix and Professor Upton’s ground-breaking science, there is huge potential to